Single User License
INR 128560
Site License
INR 257120
Corporate User License
INR 385680

Service Tax Additional

select a format

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Encephalomyelitis-Pipeline Review, H1 2015

Encephalomyelitis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6278IDB
  • |
  • Pages: 48
  • |
  • February 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Encephalomyelitis-Pipeline Review, H1 2015


Global Markets Direct's, 'Encephalomyelitis-Pipeline Review, H1 2015', provides an overview of the Encephalomyelitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Encephalomyelitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Encephalomyelitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Encephalomyelitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Encephalomyelitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Encephalomyelitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Encephalomyelitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Encephalomyelitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Encephalomyelitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Encephalomyelitis Overview 6

Therapeutics Development 7

Pipeline Products for Encephalomyelitis-Overview 7

Pipeline Products for Encephalomyelitis-Comparative Analysis 8

Encephalomyelitis-Therapeutics under Development by Companies 9

Encephalomyelitis-Therapeutics under Investigation by Universities/Institutes 10

Encephalomyelitis-Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Encephalomyelitis-Products under Development by Companies 13

Encephalomyelitis-Products under Investigation by Universities/Institutes 14

Encephalomyelitis-Companies Involved in Therapeutics Development 15

Effimune SAS 15

Endocyte, Inc. 16

Immune Technologies and Medicine 17

InteKrin Therapeutics, Inc. 18

Io Therapeutics, Inc. 19

Merck & Co., Inc. 20

Momenta Pharmaceuticals, Inc. 21

Encephalomyelitis-Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 28

Drug Profiles 30

Anatabine-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Antibody for Autoimmune Disorders and Inflammation-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

EC-1496-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

FR-104-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

INT-131-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

IRX-5183-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Peptides for Central Nervous System and Musculoskeletal Disorders-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

PETIR-001-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

PSA-20-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

SCH-546738-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Small Molecules to Antagonize VLA-4 for Arthritis, Asthma and Encephalomyelitis-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

thymulin-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Encephalomyelitis-Recent Pipeline Updates 44

Encephalomyelitis-Dormant Projects 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

Number of Products under Development for Encephalomyelitis, H1 2015 7

Number of Products under Development for Encephalomyelitis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Development, H1 2015 12

Products under Development by Companies, H1 2015 13

Products under Investigation by Universities/Institutes, H1 2015 14

Encephalomyelitis-Pipeline by Effimune SAS, H1 2015 15

Encephalomyelitis-Pipeline by Endocyte, Inc., H1 2015 16

Encephalomyelitis-Pipeline by Immune Technologies and Medicine, H1 2015 17

Encephalomyelitis-Pipeline by InteKrin Therapeutics, Inc., H1 2015 18

Encephalomyelitis-Pipeline by Io Therapeutics, Inc., H1 2015 19

Encephalomyelitis-Pipeline by Merck & Co., Inc., H1 2015 20

Encephalomyelitis-Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 21

Assessment by Monotherapy Products, H1 2015 22

Number of Products by Stage and Target, H1 2015 24

Number of Products by Stage and Mechanism of Action, H1 2015 26

Number of Products by Stage and Route of Administration, H1 2015 27

Number of Products by Stage and Molecule Type, H1 2015 29

Encephalomyelitis Therapeutics-Recent Pipeline Updates, H1 2015 44

Encephalomyelitis-Dormant Projects, H1 2015 46

List of Figures

Number of Products under Development for Encephalomyelitis, H1 2015 7

Number of Products under Development for Encephalomyelitis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Early Stage Products, H1 2015 12

Assessment by Monotherapy Products, H1 2015 22

Number of Products by Top 10 Targets, H1 2015 23

Number of Products by Stage and Top 10 Targets, H1 2015 24

Number of Products by Top 10 Mechanism of Actions, H1 2015 25

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 26

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27

Number of Products by Top 10 Molecule Types, H1 2015 28

Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Effimune SAS

Endocyte, Inc.

Immune Technologies and Medicine

InteKrin Therapeutics, Inc.

Io Therapeutics, Inc.

Merck & Co., Inc.

Momenta Pharmaceuticals, Inc.

Encephalomyelitis Therapeutic Products under Development, Key Players in Encephalomyelitis Therapeutics, Encephalomyelitis Pipeline Overview, Encephalomyelitis Pipeline, Encephalomyelitis Pipeline Assessment

Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]